These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
    Author: Papageorgiou SG, Tsiodras S, Siakallis G, Bazani E, Spathis A, Poulakou G, Korkolopoulou P, Panayiotides I, Pappa V.
    Journal: Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951.
    Abstract:
    Anti-CD20-based chemo-immunotherapeutic regimens have been suggested to assist in the management of Epstein-Barr virus (EBV)-induced hemophagocytic lymphohistiocytosis (HLH) and EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD), by reducing EBV viral load and EBV-induced inflammation. Herein we report a fatal EBV-related HLH in the context of Hodgkin lymphoma (HL)-like Richter's transformation of B chronic lymphocytic leukemia (B-CLL), two months after rituximab treatment. The complex balance between EBV driven T-cell stimulation and immunosuppressive therapy in the context of multiple immune deficits is discussed.
    [Abstract] [Full Text] [Related] [New Search]